Immunic Inc IMUX

NAS: IMUX | ISIN: US4525EP1011   3/05/2024
1,370 USD (+3,01%)
(+3,01%)   3/05/2024

1 mei 2024 · Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update · Persbericht

30 april 2024 · Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation · Persbericht

4 april 2024 · Immunic to Host MS R&D Day and Participate in Investor Conferences in April · Persbericht

20 maart 2024 · Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States · Persbericht

7 maart 2024 · Immunic to Participate in Investor and Scientific Conferences in March · Persbericht

29 februari 2024 · Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 · Persbericht

22 februari 2024 · Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update · Persbericht

15 februari 2024 · Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update · Persbericht

1 februari 2024 · Immunic to Participate in Investor and Scientific Conferences in February · Persbericht

5 januari 2024 · Immunic Highlights 2023 Accomplishments and Upcoming Milestones · Persbericht

5 januari 2024 · Immunic, Inc. Announces Private Placement of up to $240 Million · Persbericht

7 november 2023 · Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update · Persbericht

2 november 2023 · Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts · Persbericht

26 oktober 2023 · Immunic to Participate in Scientific and Industry Conferences in November · Persbericht

16 oktober 2023 · Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023 · Persbericht

15 oktober 2023 · Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023 · Persbericht

11 oktober 2023 · Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting · Persbericht

10 oktober 2023 · Thinking about buying stock in Immunic, BioXcel Therapeutics, Coherent Corp, Emx Royalty, or Lexicon Pharmaceuticals? · Persbericht

9 oktober 2023 · Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis · Persbericht

4 oktober 2023 · Immunic to Participate in Scientific Conferences in October · Persbericht

Mijn selecties